{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:08:09Z","timestamp":1793362089701,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cgh.2026.03.012","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:25:22Z","timestamp":1774373122000},"page":"2297-2304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["ORP-101 in Irritable Bowel Syndrome With Diarrhea: A Phase II Randomized, Controlled Trial"],"prefix":"10.1016","volume":"24","author":[{"given":"Prashant","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy W.","family":"Nee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ballou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4956-1612","authenticated-orcid":false,"given":"Jack","family":"Loesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Iturrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Rangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-1188","authenticated-orcid":false,"given":"Anthony","family":"Lembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2026.03.012_bib1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41575-025-01065-9","article-title":"Common misconceptions and controversies in the management of irritable bowel syndrome","volume":"22","author":"Black","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.03.012_bib2","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S2468-1253(20)30217-X","article-title":"Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis","volume":"5","author":"Oka","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2026.03.012_bib3","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.3748\/wjg.v21.i26.8103","article-title":"Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation","volume":"21","author":"Singh","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.03.012_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/j.gastro.2022.04.017","article-title":"AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea","volume":"163","author":"Lembo","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.03.012_bib5","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1053\/j.gastro.2019.10.036","article-title":"Use of treatments for irritable bowel syndrome and patient satisfaction based on the IBS in America survey","volume":"158","author":"Rangan","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.03.012_bib6","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1476-5381.2012.02068.x","article-title":"Modulation of gastrointestinal function by MuDelta, a mixed \u03bc opioid receptor agonist\/ \u03bc opioid receptor antagonist","volume":"167","author":"Wade","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cgh.2026.03.012_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.642493","article-title":"The role of the kappa opioid system in comorbid pain and psychiatric disorders: function and implications","volume":"15","author":"Ji","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1016\/j.cgh.2026.03.012_bib8","doi-asserted-by":"crossref","first-page":"S1306","DOI":"10.1016\/S0016-5085(17)34353-6","article-title":"A novel partial \u03bc agonist \u03ba antagonist for the treatment of IBS-D without the risk of pancreatitis\/sphincter of Oddi spasm","volume":"152","author":"Pasricha","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2026.03.012_bib9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/j.1572-0241.2000.01941.x","article-title":"Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire","volume":"95","author":"Drossman","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.03.012_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2026.03.012_bib11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/1756283X17726018","article-title":"Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population","volume":"10","author":"Delgado-Herrera","year":"2017","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2026.03.012_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.03.012_bib13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2026.03.012_bib14","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/ajg.2017.72","article-title":"Eluxadoline efficacy in IBS-D patients who report prior loperamide use","volume":"112","author":"Lacy","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2026.03.012_bib15","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/apt.17426","article-title":"Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: the TRITON trial","volume":"57","author":"Gunn","year":"2023","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526002168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356526002168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:03:09Z","timestamp":1785974589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356526002168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1542356526002168"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2026.03.012","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ORP-101 in Irritable Bowel Syndrome With Diarrhea: A Phase II Randomized, Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.01.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2026.01.014","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}]}}